AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development often lacks precise understanding of how diseases manifest at the organ level, hindering the creation of targeted and effective treatments. Current methods struggle to integrate diverse omics data to provide a comprehensive view of organ-specific disease mechanisms.
Solution
AIVIVO LTD develops AI-driven systems that generate and analyze multi-modal omics data to construct "OrganoMaps." These OrganoMaps link disease biology with potential treatment interventions at the organ level, providing a detailed understanding of disease mechanisms. By decoding disease at the organ level, AIVIVO enables the development of novel, targeted medicines tailored to specific organ-related conditions. This approach facilitates a more precise and effective drug discovery process, ultimately benefiting patients in need of specialized treatments.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for organ-specific diseases.
Features
- AI-powered systems for generating multi-modal omics data.
- Construction of OrganoMaps linking disease biology and treatment interventions.
- Organ-level analysis of disease mechanisms.
- Identification of potential targets for drug development.